{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:03:49Z","timestamp":1790935429481,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1136\/ard.2005.044958","type":"journal-article","created":{"date-parts":[[2005,12,9]],"date-time":"2005-12-09T01:43:39Z","timestamp":1134092619000},"page":"654-661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":254,"title":["Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study"],"prefix":"10.1016","volume":"65","author":[{"given":"J-Y","family":"Reginster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Adami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Lakatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Greenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J J","family":"Stepan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S L","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Rowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Mairon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Bonvoisin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M K","family":"Drezner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Emkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Felsenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P D","family":"Delmas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P D","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2005.044958_bib1","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/jbmr.5650070902","article-title":"Perspective. How many women have osteoporosis?","volume":"7","author":"Melton","year":"1992","journal-title":"J Bone Miner Res"},{"key":"10.1136\/ard.2005.044958_bib2","unstructured":"International Osteoporosis Foundation. Osteoporosis in the European community: action plan. International Osteoporosis Foundation, 2003. Available from, http:\/\/www.osteofound.org\/advocacy_policy\/eu_policy_project\/pdf\/action_plan_03_e.pdf (accessed 12 January 2006)."},{"key":"10.1136\/ard.2005.044958_bib3","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1359\/jbmr.2003.18.6.1139","article-title":"Adverse outcomes of osteoporotic fractures in the general population","volume":"18","author":"Melton","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1136\/ard.2005.044958_bib4","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1136\/ard.2005.044958_bib5","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s00198-004-1602-9","article-title":"Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study","volume":"15","author":"Delmas","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1136\/ard.2005.044958_bib6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1136\/ard.2005.044958_bib7","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1136\/ard.2005.044958_bib8","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1136\/ard.2005.044958_bib9","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00223-004-0286-7","article-title":"Seven years of treatment with risedronate in women with postmenopausal osteoporosis","volume":"75","author":"Mellstrom","year":"2004","journal-title":"Calcif Tissue Int"},{"key":"10.1136\/ard.2005.044958_bib10","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years\u00e2\u20ac\u2122 experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2005.044958_bib11","doi-asserted-by":"crossref","unstructured":"Haynes RB, McDonald H, Garg AX, Montague P. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev 2002; (2): CD000011.","DOI":"10.1002\/14651858.CD000011"},{"key":"10.1136\/ard.2005.044958_bib12","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","article-title":"A systematic review of the associations between dose regimens and medication compliance","volume":"23","author":"Claxton","year":"2001","journal-title":"Clin Ther"},{"issue":"suppl 3","key":"10.1136\/ard.2005.044958_bib13","first-page":"S83","article-title":"Patient preference for once-monthly over once-weekly bisphosphonate treatment [abstract]","volume":"16","author":"\u00c3\u2026kesson","year":"2005","journal-title":"Osteoporos Int"},{"issue":"suppl 1","key":"10.1136\/ard.2005.044958_bib14","first-page":"S448","article-title":"Does dosing regimen impact persistence with bisphosphonate therapy among postmenopausal osteoporotic women? [abstract]","volume":"19","author":"Cramer","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"suppl","key":"10.1136\/ard.2005.044958_bib15","first-page":"S513","article-title":"Medication persistence is improved with less frequent dosing of bisphosphonates, but remains inadequate [abstract]","volume":"50","author":"Ettinger","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"suppl 3","key":"10.1136\/ard.2005.044958_bib16","first-page":"S45","article-title":"Persistence and compliance with daily- and weekly-administered bisphosphonates in German women with osteoporosis [abstract]","volume":"16","author":"Bartl","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1136\/ard.2005.044958_bib17","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00198-004-1652-z","article-title":"The impact of compliance with osteoporosis therapy on fracture rates in actual practice","volume":"15","author":"Caro","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1136\/ard.2005.044958_bib18","first-page":"P297","article-title":"Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the Impact Study [abstract]","volume":"72","author":"Eastell","year":"2003","journal-title":"Calcif Tissue Int"},{"issue":"suppl 1","key":"10.1136\/ard.2005.044958_bib19","first-page":"S107","article-title":"Longer-term effectiveness outcomes of non-compliance and non-persistence with daily-regimen bisphosphonate therapy in patients with osteoporosis treated in tertiary specialist care [abstract]","volume":"15","author":"Sebaldt","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1136\/ard.2005.044958_bib20","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/jbmr.5650060915","article-title":"BM 21.0955, a potent new bisphosphonate to inhibit bone resorption","volume":"6","author":"M\u00c3\u00bchlbauer","year":"1991","journal-title":"J Bone Miner Res"},{"key":"10.1136\/ard.2005.044958_bib21","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00198-004-1612-7","article-title":"Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing","volume":"15","author":"Bauss","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1136\/ard.2005.044958_bib22","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1210\/jc.2004-1750","article-title":"Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study","volume":"90","author":"Reginster","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1136\/ard.2005.044958_bib23","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1359\/JBMR.050313","article-title":"Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE Study","volume":"20","author":"Miller","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1136\/ard.2005.044958_bib24","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jcem.85.1.6267","article-title":"Antifracture efficacy of antiresorptive agents are related to changes in bone density","volume":"85","author":"Wasnich","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1136\/ard.2005.044958_bib25","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jcem.87.4.8415","article-title":"Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents","volume":"87","author":"Hochberg","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1136\/ard.2005.044958_bib26","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1359\/jbmr.2003.18.10.1789","article-title":"Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use. The OFELY study","volume":"18","author":"Garnero","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1136\/ard.2005.044958_bib27","first-page":"1905","article-title":"ICH harmonized tripartite guideline. Statistical principles for clinical trials","volume":"18","year":"1999","journal-title":"Statist Med"},{"key":"10.1136\/ard.2005.044958_bib28","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.bone.2003.12.022","article-title":"Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy","volume":"34","author":"Delmas","year":"2004","journal-title":"Bone"},{"key":"10.1136\/ard.2005.044958_bib29","unstructured":"Website. Alendronate prescribing information. http:\/\/www.fosamax.com (accessed 12 January 2006)."},{"key":"10.1136\/ard.2005.044958_bib30","unstructured":"Wensite. Risedronate prescribing information. http:\/\/www.actonel.com (accessed 12 January 2006)."}],"updated-by":[{"DOI":"10.1136\/ard.2005.044958.corr1","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000}}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724201941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724201941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2005.044958","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T01:20:29Z","timestamp":1737249629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724201941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S0003496724201941"],"URL":"https:\/\/doi.org\/10.1136\/ard.2005.044958","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2005.044958","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Copyright 2006 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}